Acromegaly Clinical Trial
Official title:
Developing a Simple Recognition System of Acromegaly
We will compare the features of 3D stereophotography of acromegaly patients with that of healthy people. We hope to develop a computerized model to help screening acromegaly patients for early detection and treatment.
Background: Acromegaly is a slowly progressive disease caused by growth hormone (GH) excess.
The estimated prevalence of the disease is 40 cases/1000000 population with 3-4 new
cases/1000000 population per year. Most patients have classic manifestations due to acral
and soft tissue change, including thickening of the calvarium, increased size of frontal
sinus, enlargement of the nose, prognathism, and widely spaced teeth. The hands and feet are
large, thickened and bulky. Acromegaly was also associated with many comorbidities including
cardiovascular complications (acromegalic cardiomyopathy and arterial hypertension),
respiratory complications (sleep apnea), metabolic complication (impaired glucose tolerance,
diabetes mellitus), joint and bone complications (carpal-tunnel syndrome, osteoarthritis).3
The outcome of growth hormone level suppression after transsphenoidal surgery is far better
for microadenomas (80-90%) than for macroadenomas (less than 50%). Furthermore, higher
growth hormone level at diagnosis was related to poor prognosis. An early detection of
acromegaly with early intervention was desirable. However, due to the slowly progression of
the disease, times from symptom onset to diagnosis were 5.2 to 5.9 year4.
Current method to diagnose patients with acromegaly was to check serum GH and insulin-like
growth factor 1 (IGF-1). However, tests for growth hormone and IGF-1 are currently
unavailable in most hospitals in Taiwan and were expensive. We want to find a better
screening tool for acromegaly with less expensive and high efficacy. Due to specific facial
appearance of acromegaly, there were studies to recognize acromegaly by computer
program1,2,3. They tried to develop computer programs to separate facial photographs of
patient with acromegaly and normal subjects. The accuracy could reach 71.9% to 86%. Due to
enlarged hand with increased soft tissue in patients with acromegaly, we also want to
compare the difference of face, hand and feet morphology and face, hand and feet X ray of
acromegaly patients with those of normal population. We hope to set a computer model to
early detect acromegaly patients in Chinese people.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06344650 -
Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. Cross-sectional and Prospective Study
|
||
Active, not recruiting |
NCT02092129 -
Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly.
|
N/A | |
Completed |
NCT02012127 -
Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
|
||
Active, not recruiting |
NCT01265121 -
Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism.
|
N/A | |
Terminated |
NCT00765323 -
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
|
Phase 3 | |
Completed |
NCT00500227 -
Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
|
||
Completed |
NCT00531908 -
Physiopathology of Sodium Retention in Acromegaly
|
N/A | |
Completed |
NCT01278342 -
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
|
Phase 4 | |
Active, not recruiting |
NCT01809808 -
A Prospective Study of Outcome After Therapy for Acromegaly
|
||
Completed |
NCT00145405 -
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
|
Phase 4 | |
Completed |
NCT00210457 -
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
|
Phase 3 | |
Recruiting |
NCT05401084 -
Diet in the Management of Acromegaly
|
N/A | |
Recruiting |
NCT00005100 -
Measurement of Outcome of Surgical Treatment in Patients With Acromegaly
|
N/A | |
Completed |
NCT00521300 -
Preoperative Octreotide Treatment of Acromegaly
|
Phase 4 | |
Completed |
NCT03548415 -
Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
|
Phase 2 | |
Not yet recruiting |
NCT04066569 -
Reproducibility and Utility of OGTT in Acromegaly
|
N/A | |
Not yet recruiting |
NCT05298891 -
Hypoproteic Diet in Acromegaly
|
N/A | |
Recruiting |
NCT04520646 -
A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
|
N/A | |
Not yet recruiting |
NCT04529356 -
The TMS Treatment for Postoperative Headache in GH Tumor
|
N/A | |
Active, not recruiting |
NCT03252353 -
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
|
Phase 3 |